Literature DB >> 20719956

Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Brett D Welch1, J Nicholas Francis, Joseph S Redman, Suparna Paul, Matthew T Weinstock, Jacqueline D Reeves, Yolanda S Lie, Frank G Whitby, Debra M Eckert, Christopher P Hill, Michael J Root, Michael S Kay.   

Abstract

The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly conserved, and essential for viral entry. Here, we report on the design of a pocket-specific D-peptide, PIE12-trimer, that is extraordinarily elusive to resistance and characterize its inhibitory and structural properties. D-peptides (peptides composed of D-amino acids) are promising therapeutic agents due to their insensitivity to protease degradation. PIE12-trimer was designed using structure-guided mirror-image phage display and linker optimization and is the first D-peptide HIV entry inhibitor with the breadth and potency required for clinical use. PIE12-trimer has an ultrahigh affinity for the gp41 pocket, providing it with a reserve of binding energy (resistance capacitor) that yields a dramatically improved resistance profile compared to those of other fusion inhibitors. These results demonstrate that the gp41 pocket is an ideal drug target and establish PIE12-trimer as a leading anti-HIV antiviral candidate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719956      PMCID: PMC2953169          DOI: 10.1128/JVI.01339-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.

Authors:  D M Eckert; V N Malashkevich; L H Hong; P A Carr; P S Kim
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.

Authors:  M Ferrer; T M Kapoor; T Strassmaier; W Weissenhorn; J J Skehel; D Oprian; S L Schreiber; D C Wiley; S C Harrison
Journal:  Nat Struct Biol       Date:  1999-10

3.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

4.  Construction of high-complexity combinatorial phage display peptide libraries.

Authors:  K A Noren; C J Noren
Journal:  Methods       Date:  2001-02       Impact factor: 3.608

5.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 6.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

7.  Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; Z Zhang; W A O'Brien; L Ratner; G M Shaw; E Hunter
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.

Authors:  B S Jin; J R Ryu; K Ahn; Y G Yu
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-20       Impact factor: 2.205

9.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.

Authors:  A K Debnath; L Radigan; S Jiang
Journal:  J Med Chem       Date:  1999-08-26       Impact factor: 7.446

View more
  77 in total

1.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Shengwen Xiong; Yuanyuan Qiao; Zonglin Qiu; Yuxian He
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

Review 4.  Targeting recognition surfaces on natural proteins with peptidic foldamers.

Authors:  James W Checco; Samuel H Gellman
Journal:  Curr Opin Struct Biol       Date:  2016-07-05       Impact factor: 6.809

Review 5.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

6.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

7.  Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury.

Authors:  Michael R Pope; Urska Bukovnik; John M Tomich; Sherry D Fleming
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

Review 8.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure.

Authors:  Marcelo T Augusto; Axel Hollmann; Miguel A R B Castanho; Matteo Porotto; Antonello Pessi; Nuno C Santos
Journal:  J Antimicrob Chemother       Date:  2014-01-23       Impact factor: 5.790

Review 10.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.